This HTML5 document contains 133 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://dx.doi.org/10.1177/
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q57601863
rdf:type
wikibase:Item
schema:description
teaduslik artikkel บทความทางวิทยาศาสตร์ artigo científico (publicado na 2012) 2012年學術文章 مقالة علمية vitskapeleg artikkel مقالهٔ علمی articolo scientifico artikull shkencor tieteellinen artikkeli bilimsel makale научни чланак 2012年学术文章 wetenschappelijk artikel ২০১২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ artigo científico επιστημονικό άρθρο vetenskaplig artikel 2012年学术文章 artykuł naukowy мақолаи илмӣ научная статья 2012年学术文章 im März 2012 veröffentlichter wissenschaftlicher Artikel vitenskapelig artikkel article scientific vědecký článek mokslinis straipsnis scienca artikolo мақолаи илмӣ tudományos cikk artigo científico (publicado na 2012) article científic 2012년 논문 2012年學術文章 գիտական հոդված 2012年学术文章 سائنسی مضمون article scientifique publié en 2012 სამეცნიერო სტატია artículo científico publicado en 2012 articol științific naučni članak 2012年學術文章 vedecký článok bài báo khoa học artículu científicu espublizáu en marzu de 2012 научна статия 2012年學術文章 מאמר מדעי 2012 nî lūn-bûn artikulong pang-agham 2012年學術文章 videnskabelig artikel (udgivet 2012) наукова стаття, опублікована в березні 2012 2012年の論文 2012年学术文章 научни чланак 2012年學術文章 scientific article published on 01 March 2012
p:P577
wds:Q57601863-FE901ACC-DB97-46B0-8BED-1C521F7D0B32
wdt:P577
2012-03-01T00:00:00Z
p:P2860
wds:Q57601863-315E45BF-4B7D-4699-888A-6A01764D3C8F wds:Q57601863-32D6A4DE-48D0-44E0-8164-003DA2FDBAE0 wds:Q57601863-0DA5A8FF-6FD1-4C33-8DD6-02CEE4E756D3 wds:Q57601863-26B371F9-FFFE-4D91-ABD6-2E57D7A72C5A wds:Q57601863-93DA8880-4299-4C3E-AA6B-95F807A388A5 wds:Q57601863-68194200-DBC3-4731-87FC-B06E2454AC98 wds:Q57601863-722997FD-F120-495A-B022-891E79B3D2BF wds:Q57601863-72FDFEEE-D4F5-477D-8F24-B9CE1EC80BCE
wdt:P2860
wd:Q34626219 wd:Q48414534 wd:Q28243804 wd:Q44825022 wd:Q34619064 wd:Q22241644 wd:Q47763052 wd:Q29616119
p:P2093
wds:Q57601863-B2C5D596-7FB2-4312-87C3-E1F3DB9E558D wds:Q57601863-8429A693-9D03-433B-837C-AED968AF7AC9 wds:Q57601863-4AF33766-E95A-4A0D-8DCA-15D1DB244912 wds:Q57601863-6728F462-A88B-4B7A-B34E-B58CEA2237D1 wds:Q57601863-62A6536D-0285-4CC0-9C35-D3A0FDFDA298 wds:Q57601863-384DBC69-3B46-4EBF-864D-2D8B04DDB6BC
wdt:P2093
Rosalía Horno Carlos Nos Joaquín Castilló M José Vicente Ana Caminero Manuel Comabella
rdfs:label
Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision
skos:prefLabel
Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision
schema:name
Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision
p:P50
wds:Q57601863-074B7116-F39C-46DF-BE10-CA9AF5A426A4 wds:Q57601863-3986B6D3-7B5A-4E8E-8295-AADDC8F7C075 wds:Q57601863-9426B702-C71D-45DE-BE08-67E6BF1C38F2 wds:Q57601863-99A8761D-D4D2-441C-B242-62A5BFBBF28B wds:Q57601863-AF0F7ABC-FBF3-42C4-976D-7D6CD2387D02 wds:Q57601863-BF7A2495-3E12-46B5-94C2-14BE341C0C37 wds:Q57601863-D3BB397E-6AC4-4E25-8A4C-C9B73C882C99 wds:Q57601863-522C2323-AB7A-48B0-95C5-94D7E92A1EFC wds:Q57601863-93AD52C2-F613-460B-B12A-0176B9C4B335
wdt:P50
wd:Q71129025 wd:Q50072184 wd:Q57064308 wd:Q58685335 wd:Q58685883 wd:Q64447514 wd:Q57011728 wd:Q41423156 wd:Q58685888
p:P1476
wds:Q57601863-5C5E1351-6B67-4B55-BEE5-81C37AB77B78
wdt:P1476
Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision
p:P304
wds:Q57601863-817EC0E7-2E92-4930-8F7B-32F06A3E782B
wdt:P304
1193-1196
p:P31
wds:Q57601863-478325ED-16C5-46E2-9D9A-4A10DADE4926
wdt:P31
wd:Q13442814
p:P698
wds:Q57601863-FDFDC353-6FA6-4DE8-A435-8DC222E893AD
wdtn:P698
n10:22383232
wdt:P698
22383232
p:P1433
wds:Q57601863-D2D53A25-3FA7-48D1-91AD-710D3DAADF96
wdt:P1433
wd:Q1952449
p:P433
wds:Q57601863-647906C9-8014-4754-8AAA-72BDA0AE111D
p:P478
wds:Q57601863-78DA9576-F5D7-4270-B0EF-946EA894ABC9
wdt:P433
8
wdt:P478
18
p:P356
wds:Q57601863-3FFF79DD-363A-495C-A94A-55BB87A46922
wdtn:P356
n12:1352458512439238
wdt:P356
10.1177/1352458512439238